989 related articles for article (PubMed ID: 3512077)
1. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.
Micetich KC; Barnes D; Erickson LC
Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
4. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
6. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.
Plooy AC; van Dijk M; Lohman PH
Cancer Res; 1984 May; 44(5):2043-51. PubMed ID: 6538808
[TBL] [Abstract][Full Text] [Related]
7. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
8. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients.
Terheggen PM; Dijkman R; Begg AC; Dubbelman R; Floot BG; Hart AA; den Engelse L
Cancer Res; 1988 Oct; 48(19):5597-603. PubMed ID: 3046743
[TBL] [Abstract][Full Text] [Related]
10. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
Roberts JJ; Friedlos F
Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
[TBL] [Abstract][Full Text] [Related]
11. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).
Holford J; Raynaud F; Murrer BA; Grimaldi K; Hartley JA; Abrams M; Kelland LR
Anticancer Drug Des; 1998 Jan; 13(1):1-18. PubMed ID: 9474239
[TBL] [Abstract][Full Text] [Related]
12. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
13. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.
Kasparkova J; Vojtiskova M; Natile G; Brabec V
Chemistry; 2008; 14(4):1330-41. PubMed ID: 18022972
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
15. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II)-induced DNA interstand cross-link removal and potentiation of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II) cytotoxicity by hydroxyurea and 1-beta-D-arabinofuranosylcytosine.
Swinnen LJ; Ellis NK; Erickson LC
Cancer Res; 1991 Apr; 51(8):1984-9. PubMed ID: 2009517
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
[TBL] [Abstract][Full Text] [Related]
18. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
19. Effect of hyperthermia on the action of cis-diamminedichloroplatinum(II), rhodamine 123(2) [tetrachloroplatinum(II)], rhodamine 123, and potassium tetrachloroplatinate in vitro and in vivo.
Herman TS; Teicher BA; Chan V; Collins LS; Kaufmann ME; Loh C
Cancer Res; 1988 May; 48(9):2335-41. PubMed ID: 3356001
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
Blommaert FA; Michael C; Terheggen PM; Muggia FM; Kortes V; Schornagel JH; Hart AA; den Engelse L
Cancer Res; 1993 Dec; 53(23):5669-75. PubMed ID: 8242622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
